Industry
Mizuho slashes price target on Arcutis Biotherapeutics Inc [ARQT] – find out why.
Arcutis Biotherapeutics Inc [NASDAQ: ARQT] closed the trading session at $6.06. The company report on January 29, 2024 at 8:00 AM that Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial. Novel steroid-free
